RANOS
Latest analyst report, hope it works..
Key takeaway:
"Impact
These figures provide insight into the potential future sales of Sofpironium Bromide in the United States, underscoring the considerable market opportunity at hand. Based on our analysis, we estimate Kaken sold ~72,000 prescriptions in 2Q, or +287,000 prescriptions on an annualised basis (Figure 4).More so, when applied to our estimate of US pricing (US$540/month; net), this annualised 2Q prescription figure implies ~A$239 million of annual revenues in the United States (Figure 5).Additionally, this is based on Japanese prescription volumes, the United States has a population nearly 3x larger than Japan – which would suggest even larger potential prescription volumes and sales are possible. "
- Forums
- ASX - By Stock
- BOT
- BOT - Anything but charting
BOT - Anything but charting, page-6664
-
- There are more pages in this discussion • 2,662 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
39.5¢ |
Change
0.010(2.60%) |
Mkt cap ! $714.9M |
Open | High | Low | Value | Volume |
39.0¢ | 40.5¢ | 37.5¢ | $4.833M | 12.29M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 511746 | 39.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 99994 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 511746 | 0.390 |
5 | 484252 | 0.385 |
6 | 390723 | 0.380 |
10 | 719851 | 0.375 |
10 | 1020257 | 0.370 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 99994 | 1 |
0.400 | 682064 | 7 |
0.405 | 165176 | 7 |
0.410 | 327323 | 15 |
0.415 | 280410 | 2 |
Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |